Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386410991> ?p ?o ?g. }
- W4386410991 abstract "Glioblastoma is the most aggressive primary brain cancer with a poor prognosis. Despite numerous studies in the past 17 years, effective treatment options for glioblastoma remain limited. In this study, we aimed to identify and compare phase III clinical trials for glioblastoma in terms of efficacy and baseline characteristics.A systematic literature search was conducted using PubMed and ClinicalTrials.gov to identify phase III clinical trials for glioblastoma in adult patients. The target population included adult patients aged 18 years and above (younger cohort) and patients ≥60 years of age (elderly cohort). The search results were screened based on predefined inclusion criteria, and the included trials were analyzed for their study design, baseline characteristics, and survival results.Eleven trials met the inclusion criteria in the younger cohort. Of these, three reported a statistically significant improvement in overall survival (OS), including the EORTC/NCIC study (NCT00006353), EF-14 (NCT00916409), and CeTeG (NCT01149109). Of the 11 trials, eight were open-label randomized trials, including all of the positive ones, while three negative trials employed treatment blinding and a placebo control. The baseline characteristics of the trials [such as extent of resection, age, gender, and O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status] did not significantly differ between positive and negative trials. Isocitrate dehydrogenase (IDH) mutation status was analyzed in only two trials, with a small percentage of IDH-mutated tumors in each. Additionally, three more trials in the elderly cohort showed a statistically significant improvement of OS, the NOA-08 trial, the ISRCTN81470623-trial by Malmström et al. and NCT00482677-trial by Perry et al. Their baseline characteristics and implications are also analyzed.This analysis of phase III clinical trials for glioblastoma conducted since 2005 showed that the majority of trials did not result in a significant improvement in OS. Among the trials included in this analysis, only the EORTC/NCIC, EF-14, and CeTeG studies demonstrated a positive OS outcome in the younger cohort." @default.
- W4386410991 created "2023-09-05" @default.
- W4386410991 creator A5001167896 @default.
- W4386410991 creator A5003159414 @default.
- W4386410991 creator A5031780975 @default.
- W4386410991 creator A5041144526 @default.
- W4386410991 creator A5051467826 @default.
- W4386410991 creator A5052523213 @default.
- W4386410991 creator A5074474133 @default.
- W4386410991 creator A5074697803 @default.
- W4386410991 creator A5088964414 @default.
- W4386410991 date "2023-01-01" @default.
- W4386410991 modified "2023-10-11" @default.
- W4386410991 title "Are we providing best available care to newly diagnosed glioblastoma patients? - Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022" @default.
- W4386410991 cites W1641007866 @default.
- W4386410991 cites W2074885018 @default.
- W4386410991 cites W2084112669 @default.
- W4386410991 cites W2096287682 @default.
- W4386410991 cites W2096560594 @default.
- W4386410991 cites W2098950184 @default.
- W4386410991 cites W2101922439 @default.
- W4386410991 cites W2107731988 @default.
- W4386410991 cites W2107803747 @default.
- W4386410991 cites W2115516828 @default.
- W4386410991 cites W2124736921 @default.
- W4386410991 cites W2126547063 @default.
- W4386410991 cites W2132607958 @default.
- W4386410991 cites W2135947790 @default.
- W4386410991 cites W2147016542 @default.
- W4386410991 cites W2148977460 @default.
- W4386410991 cites W2154526619 @default.
- W4386410991 cites W2156330848 @default.
- W4386410991 cites W2158681922 @default.
- W4386410991 cites W2165871546 @default.
- W4386410991 cites W2166935005 @default.
- W4386410991 cites W2196065821 @default.
- W4386410991 cites W2205491921 @default.
- W4386410991 cites W2295059886 @default.
- W4386410991 cites W2386040222 @default.
- W4386410991 cites W2526477473 @default.
- W4386410991 cites W2599750069 @default.
- W4386410991 cites W2626539441 @default.
- W4386410991 cites W2749747068 @default.
- W4386410991 cites W2778283729 @default.
- W4386410991 cites W2791377051 @default.
- W4386410991 cites W2877519050 @default.
- W4386410991 cites W2914199948 @default.
- W4386410991 cites W2942152468 @default.
- W4386410991 cites W2945539848 @default.
- W4386410991 cites W2996450468 @default.
- W4386410991 cites W3020099303 @default.
- W4386410991 cites W3095995374 @default.
- W4386410991 cites W3097339274 @default.
- W4386410991 cites W3155545925 @default.
- W4386410991 cites W3174246647 @default.
- W4386410991 cites W3207959735 @default.
- W4386410991 cites W4200001037 @default.
- W4386410991 cites W4211220688 @default.
- W4386410991 cites W4211260562 @default.
- W4386410991 cites W4223897107 @default.
- W4386410991 cites W4225630787 @default.
- W4386410991 cites W4293032760 @default.
- W4386410991 doi "https://doi.org/10.1093/noajnl/vdad105" @default.
- W4386410991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37811538" @default.
- W4386410991 hasPublicationYear "2023" @default.
- W4386410991 type Work @default.
- W4386410991 citedByCount "0" @default.
- W4386410991 crossrefType "journal-article" @default.
- W4386410991 hasAuthorship W4386410991A5001167896 @default.
- W4386410991 hasAuthorship W4386410991A5003159414 @default.
- W4386410991 hasAuthorship W4386410991A5031780975 @default.
- W4386410991 hasAuthorship W4386410991A5041144526 @default.
- W4386410991 hasAuthorship W4386410991A5051467826 @default.
- W4386410991 hasAuthorship W4386410991A5052523213 @default.
- W4386410991 hasAuthorship W4386410991A5074474133 @default.
- W4386410991 hasAuthorship W4386410991A5074697803 @default.
- W4386410991 hasAuthorship W4386410991A5088964414 @default.
- W4386410991 hasBestOaLocation W43864109911 @default.
- W4386410991 hasConcept C126322002 @default.
- W4386410991 hasConcept C142724271 @default.
- W4386410991 hasConcept C143998085 @default.
- W4386410991 hasConcept C204787440 @default.
- W4386410991 hasConcept C27081682 @default.
- W4386410991 hasConcept C2908647359 @default.
- W4386410991 hasConcept C535046627 @default.
- W4386410991 hasConcept C71924100 @default.
- W4386410991 hasConcept C72563966 @default.
- W4386410991 hasConcept C99454951 @default.
- W4386410991 hasConceptScore W4386410991C126322002 @default.
- W4386410991 hasConceptScore W4386410991C142724271 @default.
- W4386410991 hasConceptScore W4386410991C143998085 @default.
- W4386410991 hasConceptScore W4386410991C204787440 @default.
- W4386410991 hasConceptScore W4386410991C27081682 @default.
- W4386410991 hasConceptScore W4386410991C2908647359 @default.
- W4386410991 hasConceptScore W4386410991C535046627 @default.
- W4386410991 hasConceptScore W4386410991C71924100 @default.
- W4386410991 hasConceptScore W4386410991C72563966 @default.
- W4386410991 hasConceptScore W4386410991C99454951 @default.
- W4386410991 hasIssue "1" @default.
- W4386410991 hasLocation W43864109911 @default.